Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies

NCT05862259 is registered in ClinicalTrials.gov with Xinqiao Hospital of Chongqing as lead sponsor.

NCT NCT05862259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05862259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies
Lead sponsor
Xinqiao Hospital of Chongqing
Phase
Observational
Overall status
Recruiting
Start date
August 10, 2023
Completion date
December 31, 2025
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

artificial intelligence, immunotherapy, malignant tumor